GILEAD

📅 Upcoming

🕒 Recent(90d)

News

• DPHARM: How to address the clinical trial enrollment crisis?
  Clinical trials are facing an enrollment crisis. Around 80% of trials don’t meet their enrollment timelines, and fewer than 5% of eligible adult cancer patients participate in trials.
  fiercebiotech · 22h ago
• Gilead reaches HIV PrEP agreements; Hong Kong investigates Cloudbreak IPO
  Plus news about VaxThera, Sironax, Circle Pharma, Nutshell Therapeutics, Evopoint and Sensorion. Gilead’s HIV PrEP pact in Latin America: The California drugmaker said it formed an agreement with t…
  endpoints · 1d ago
• Sionna says good-bye to 46% of staffers, including exec
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 1d ago
• WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
  The year’s biggest meeting on lung cancer research featured data suggesting a new treatment standard for an aggressive tumor as well as debate about the reliability of results from China-run studies.
  biopharma_dive · 2d ago
• Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagon
  Cellectis may have kicked off the year promising “huge momentum” in the allogeneic CAR-T space, but even the French biotech has been unable to resist the dominance of in vivo options.
  fiercebiotech · 4d ago
• STAT+: Trump’s secretive pharma deals may undermine ‘most-favored nation’ pricing, an analysis suggests
  The projected savings from Trump's "most-favored nation" pricing policy might be drastically reduced by secretive deals with pharma companies, a new analysis finds.
  stat · 4d ago
• STAT+: Pharma wins a battle over the cost of wastewater treatment in Europe
  An E.U. AG recommended annulling part of a directive that requires drugmakers to finance 80% of the costs of wastewater treatment.
  stat · 6d ago
• STAT+: Up and down the ladder: The latest comings and goings
  From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
  stat · 6d ago
• STAT+: Pharmalittle: We’re reading about anxious Novartis investors, patent expirations for biologics, and more
  Novartis investors are stepping up scrutiny of the company's dealmaking after setbacks to drugs it acquired through mergers and acquisitions
  stat · 6d ago
• Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
  Karyopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy startup…
  biopharma_dive · 6d ago